`1 min read
`Eylea pre lled syringe now available
`
`The Eylea injection pre lled syringe is now available to order, Regeneron Pharmaceuticals announced.
`
`The Eylea (a ibercept) 2 mg, single-dose, pre lled, sterilized syringe was approved in August to treat neovascular ag
`related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic
`retinopathy.
`
`Read next
`Foveal capillary perfusion density decreases in DME patients treated with a ibercept
`
`Graybug begins phase 2b trial of GB-102 to treat wet AMD
`
`Innovative Treatment Protocols
`That Can Rede ne the
`Management of nAMD and DR
`Designed to block the growth of new blood vessels and decrease the ability of uid to pass through blood vessels in th
`eye, it is the only anti-VEGF approved to treat four retinal conditions with a single dose strength pre lled syringe.
`Learn from clinical trials that assess the
`effectiveness of different anti-VEGF treatment
`protocols in the management of diabetic
`retinopathy and neovascular age-related
`diabetic macular edema
`diabetic retinopathy
`a iberce
`macular degeneration.
`
`Read more about
`
`retinal vein occlusion
`
`neovascular age-related macular degeneration
`
`June 19, 2020
`3 min read
`Which DRCR Retina Network protocol has affected the way you practice the most?
`
`Click here to read the Cover Story, "Expansion of DRCR network opens new research opportunities."
`
`EARN CREDITS
`
`Protocol T
`The protocol that has a ected the way I practice the most is Protocol T. Protocol T was a three-arm, head-to-head stu
`comparing the e cacy of a ibercept, ranibizumab and bevacizumab for center-involving diabetic macular edema (CI
`DME) and decreased best corrected visual acuity, with these anti-VEGF drugs delivered in an individualized as-neede
`fashion over a 2-year time frame. This was the rst study that showed any clinically meaningful di erences in e cac
`between the available anti-VEGF drugs for any indication, and to date, such signi cant di erences have only been
`demonstrated for DME.
`
`CONTINUE READING
`
`Regeneron Exhibit 1180.001
`Regeneron v. Novartis
`IPR2021-00816
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
